EMERGENT BIOSOLUTIONS INC. Repayments of Convertible Debt
EMERGENT BIOSOLUTIONS INC. (EBS) reported Repayments of Convertible Debt of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2024-03-08
- EMERGENT BIOSOLUTIONS INC. repayments of convertible debt for the quarter ending 2022-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. repayments of convertible debt for the quarter ending 2022-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. repayments of convertible debt for the quarter ending 2022-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. repayments of convertible debt for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. repayments of convertible debt for fiscal 2023 was $0.00.
- EMERGENT BIOSOLUTIONS INC. repayments of convertible debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. repayments of convertible debt for fiscal 2021 was $10.60M.
- EMERGENT BIOSOLUTIONS INC. repayments of convertible debt for fiscal 2020 was $0.00.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-08 | $0.00 10-K · filed 2024-03-08 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $0.00 10-Q · filed 2022-08-02 | $0.00 derived: sum of 3 quarters · filed 2024-03-08 | $0.00 derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-03-31 | $0.00 10-Q · filed 2022-04-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-08 | $0.00 derived: sum of 4 quarters · filed 2024-03-08 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-08 | $10.60M 10-K · filed 2024-03-08 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $10.60M 10-Q · filed 2022-11-09 | $10.60M derived: sum of 4 quarters · filed 2023-12-11 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $10.60M 10-Q · filed 2022-08-02 | $10.60M derived: sum of 3 quarters · filed 2023-12-11 | $10.60M derived: sum of 4 quarters · filed 2023-12-11 |
| 2021-03-31 | $10.60M 10-Q · filed 2022-04-29 | $10.60M derived: sum of 2 quarters · filed 2023-12-11 | $10.60M derived: sum of 3 quarters · filed 2023-12-11 | $10.60M derived: sum of 4 quarters · filed 2023-12-11 |
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $0.00 derived: sum of 2 quarters · filed 2023-12-11 | $0.00 derived: sum of 3 quarters · filed 2023-12-11 | $0.00 10-K/A · filed 2023-12-11 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $0.00 10-Q · filed 2021-07-30 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-04-30 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |